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Abstract 
Background: Vitamin C is an essential water-soluble nutrient that functions as a key antioxidant and has been 
proven to be effective for boosting immunity. In this study, we aimed to assess the efficacy of adding high-dose intra-
venous vitamin C (HDIVC) to the regimens for patients with severe COVID-19 disease.
Methods: An open-label, randomized, and controlled trial was conducted on patients with severe COVID-19 infec-
tion. The case and control treatment groups each consisted of 30 patients. The control group received lopinavir/rito-
navir and hydroxychloroquine and the case group received HDIVC (6 g daily) added to the same regimen.
Results: There were no statistically significant differences between two groups with respect to age and gender, 
laboratory results, and underlying diseases. The mean body temperature was significantly lower in the case group on 
the 3rd day of hospitalization (p = 0.001). Peripheral capillary oxygen saturations  (SpO2) measured at the 3rd day of 
hospitalization was also higher in the case group receiving HDIVC (p = 0.014). The median length of hospitalization in 
the case group was significantly longer than the control group (8.5 days vs. 6.5 days) (p = 0.028). There was no signifi-
cant difference in  SpO2 levels at discharge time, the length of intensive care unit (ICU) stay, and mortality between the 
two groups.
Conclusions: We did not find significantly better outcomes in the group who were treated with HDIVC in addition to 
the main treatment regimen at discharge.
Trial registration irct.ir (IRCT20200411047025N1), April 14, 2020
Keywords: COVID-19, SARS-COV-2, 2019-nCoV, Vitamin C, Pneumonia, Hydroxychloroquine, Lopinavir, Ritonavir
© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco 
mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/
zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
The coronavirus disease 2019 (COVID-19) pandemic 
which started at late 2019 and spread the world out-
rageously is caused by infection with Severe Acute 
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), 
a member of the coronaviridae family. By January 2021, 
more than two million lives have been sacrificed by this 
disease, even more deaths are expected unless proper 
management does not take into place soon, in terms 
of prevention, transmission control, and treatment. 
Ascorbic acid or ascorbate (vitamin C) is an essen-
tial water-soluble nutrient that functions as a key anti-
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neurotransmitters, and affects wound healing, energy 
metabolism, nervous system function, and immune cell 
health [1–3]. The serum level of this vitamin has been 
correlated with its effect on the endothelial function [4], 
cellular immune function [5], anti-oxidative capacity, 
neutrophil function [6], and even for treatment of cancer 
and pancreatitis [7, 8]. Intravenous (IV) administration 
increases the plasma ascorbate concentrations more than 
oral supplementation (30  mM vs. 0.2  mM, respectively) 
[9, 10].
The evidence behind theoretical possible effect of vita-
min C against COVID-19 is promising [11]. In a clinical 
study of the role of ascorbic acid against Epstein–Barr 
virus (EBV) infection showed the EBV IgG and IgM anti-
body levels reduced during IV vitamin C therapy [12]. 
Also in a case report of enterovirus/rhinovirus-induced 
acute respiratory distress syndrome (ARDS) in 2017, 
infusion of high-dose IV vitamin C (HDIVC) was associ-
ated with rapid resolution of lung injury [13]. The impact 
of vitamin C administration on alleviating lung injury 
has also been investigated and supported in other studies 
[14]. There are other studies expressing the positive effect 
of IV vitamin C in patients with severe sepsis [15–17]. 
A meta-analysis also reported the impact of vitamin C 
on decreasing the duration of intensive care unit (ICU) 
admission and mechanical ventilation care in patients 
with ARDS [18–20].
Given the positive effect of IV vitamin C for viral-
induced ARDS and its role for enhancing the function 
of immune system, we aimed to investigate the correla-
tion of the HDIVC administration with improvement 
of 2019-nCoV-induced ARDS. There is lack of data and 
clinical trials that studied this correlation recently.
Materials and methods
Participants
Between April and May 2020, 85 patients with compel-
ling clinical symptoms for diagnosis of COVID-19 were 
admitted to Ziaeian Hospital, Tehran, Iran. Based on 
the eligibility criteria (Fig. 1), 25 patients were excluded 
and 60 patients were included in the study. The inclusion 
criteria were age older than 18  years, positive COVID-
19 polymerase chain reaction (PCR) test or COVID-19 
suspicion based on clinical findings (mainly fever, dysp-
nea, dry cough), imaging findings of COVID-19 on spiral 
chest computer tomography (CT) or high-resolution CT 
(HRCT) imagings validated by a trained radiologist, clini-
cal manifestations of ARDS or myocarditis, and oxygen 
saturation lower than 93% from admission or after 48 h 
from the first COVID-19 treatment. The exclusion crite-
ria were receiving anti-retroviral therapy or immune sys-
tem booster medications in the last 3 months, no proven 
and confirmed COVID-19 disease based on the inclusion 
criteria, patients with glucose-6-phosphate dehydroge-
nase (G6PD) deficiency, patients with end-stage renal 
disease (ESRD), and pregnancy.
Study arms and treatment plans
The patients were divided into two subgroups equally by 
block randomization; the case group included 30 patients 
receiving 1.5 g vitamin C IV every 6 h for 5 days and the 
control group included 30 patients who did not receive 
vitamin C. All of the participants were also treated with 
oral lopinavir/ritonavir (Kaletra, Abbott Laborato-
ries) 400/100 mg twice daily and single stat dose of oral 
hydroxychloroquine (400  mg) on the first day of hospi-
talization according to the Iranian COVID-19 treat-
ment protocol at time of this study (it should be noted 
that based on the vast number of studies for COVID-19, 
hydroxychloroquine is not considered as mainstay in the 
protocol for COVID-19 in Iran anymore). On the first day 
of hospitalization, laboratory studies including complete 
blood count (CBC), C-reactive protein (CRP), and eryth-
rocyte sedimentation rate (ESR) were obtained. Patients 
were assessed by daily measurements of core body tem-
perature, respiratory rate (RR), heart rate (HR), and 
peripheral capillary oxygen saturations  (SpO2). The treat-
ment subsided whenever any kind of drug side effects 
appeared. Some of the patients deteriorated during the 
admission and received corticosteroid (methylpredniso-
lone 125  mg daily for 3  days). Patients were discharged 
when they achieved a stable  SpO2 > 92%, no evidence of 
respiratory distress was remaining, and were afebrile for 
at least 3 consecutive days.
Ethical considerations
In accordance to the Declaration of Helsinki, written 
informed consent was obtained from all participants 
before initiation of the study. The patients were assured 
that declining to participate in the study or leaving 
the study at any point would not affect the quality of 
their treatment and that they would thereafter receive 
the standard care. The study protocol was approved 
by the institutional review board (IRB) of Tehran Uni-
versity of Medical Sciences (TUMS) (IR.TUMS.VCR.
REC.1399.078).
Measurements and statistical analysis
In this open-label and nonblinded study, distribution of 
age, gender, initial clinical symptoms, and vital signs of 
the first day of admission were compared between the 
two groups. The vital signs including body temperature, 
RR, HR and  SpO2 were also compared on the 3rd and last 
day of treatment between the two groups as an outcome 
measure. Differences in duration of hospitalization, num-
ber of patients whose condition deteriorated and needed 
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ICU admission, length of ICU admission, and difference 
between mortality rates were measured. The primary 
endpoints in this trial were a decrease in mortality, dura-
tion of hospitalization, and need for ICU admission. Sec-
ondary endpoints were determined as improvements in 
 SpO2 and vital signs as well as the general wellbeing of 
the patient. Severity score was calculated based on the 
scoring system suggested by Altschul et  al. for predic-
tion of inpatient mortality in COVID-19 patients [21]. 
Based on this scoring system, the higher the score of the 
patient, the higher the odds of inpatient mortality.
Sample size calculation was performed for non-inferi-
ority tests of difference between two group proportions. 
We assumed an effectiveness of 65% for the intervention 
group and effectiveness of 50% for the control group. 
We also assumed a margin of non-inferiority of at least 
10% between the two groups. The power of the study was 
determined as 90% (G ∗ Power, Erdfelder, Faul, and Buch-
ner, 1996).
Data was analyzed using SPSS software (IBM Corp. 
Released 2013. IBM SPSS Statistics for Windows, Version 
22.0. Armonk, NY: IBM Corp.). Quantitative variables are 
reported by mean and standard deviation (SD) and quali-
tative variables are reported using frequency and per-
centage. Because of the normal distribution of our data 
via Shapiro–Wilk test, the independent t-test was used to 
assess the means differences and a mixed-design analy-
sis of variance model (ANOVA) was performed to evalu-
ate the effect of time on body temperature. Chi-square 
and Fisher’s exact tests were used to assess the statistical 
Fig. 1 Randomization and treatment assignment
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relationships between categorical variables. The level of 
significance was set as p-value < 0.05 for all analyses.
Results
Baseline characteristics
Demographic characteristics, underlying diseases, and 
clinical and laboratory findings are presented in Table 1. 
Male-to-female ratio was 1:1. There were no statisti-
cally significant differences between two groups consid-
ering age and gender, laboratory results and underlying 
diseases (p > 0.05). All clinical findings except for fever 
(23.33% vs. 63.33% in case and control groups, respec-
tively, p = 0.002) and myalgia (13.33% vs. 60.0% in case 
and control groups, respectively, p < 0.001) were not sig-
nificantly different between the two groups.
Outcomes
There was no significant difference in body temperature 
at the time of discharge between the two groups (p > 0.05) 
(Table 1). The mean body temperatures upon admission 
and on the 3rd day of admission were significantly higher 
in the control group (p = 0.001). The mixed-design analy-
sis of variance model (ANOVA) performed to evaluate 
the effect of time on body temperature at the time of 
admission, on the 3rd day of admission and discharge, 
showed a significant effect of time on body temperature 
(Wilk’s Lambda = 0.589, F (2,57) = 19.879, p < 0.001) 
(Fig. 2). Post hoc comparison indicated a significant dif-
ference between body temperatures at time of admis-
sion, discharge, and on the 3rd day of hospitalization 
(p < 0.001).
SpO2 at admission and discharge were not significantly 
different between the two groups (p > 0.05) (Table  1). 
 SpO2 on the 3rd day of admission was higher in the case 
group compared to the control group (median, 90.5% vs. 
88.0%, respectively, p = 0.014) (Table 1). A non-paramet-
ric Friedman test of difference among repeated measures 
of  SpO2 was conducted and there was a significant differ-
ence in mean ranks in both groups with the oxygen satu-
ration increasing significantly in both groups (p < 0.001). 
The lowest  SpO2 in the case group was 60% at admis-
sion who was discharged with 92%, and in the control 
group one patient had  SpO2 of 60% who was discharged 
with  SpO2 of 94%. Except these two cases, no patient 
had oxygen saturation below 70%. The case group had a 
median length of admission in the hospital of 8.5 (range 
7.0–12.0) days which was significantly longer than the 
control group with a median length of admission of 6.5 
(range 4.0–12.0) days. There was no significant differ-
ence in the length of ICU stay between the two groups 
(p > 0.05, Table 1). There was a non-significant higher rate 
of intubation in the case group (p > 0.05) (Table 1). Mor-
tality rate was equal in both groups (three cases in each 
group, p > 0.05). During treatment with HDIVC, none of 
the patients experienced adverse events such as head-
ache, nausea, bloating, or abdominal discomfort.
Figure  3 depicts the distribution of patients in both 
groups by their severity scores. It can be seen that despite 
minor differences between two groups, the diagram fol-
lows normal distribution and the difference between two 
groups is statistically insignificant (p = 0.651).
Discussion
Until the time of this study, no definite treatment option 
has been suggested and cleared for COVID-19. While 
this pandemic is still responsible for death of above two 
million people and infection of many more, search for 
better treatment options should never be delayed [22, 
23]. Vitamin C is an essential water-soluble nutrient that 
has important roles in our body, especially in immune 
cell functions [1, 2, 4]. Studies report that vitamin C can 
be effective in treatment of bacterial and viral infection 
[24–26]. These studies showed vitamin C weakly inhib-
its the multiplication of viruses such as influenza type 
A, Herpes simplex virus type 1 (HSV-1) and poliovirus 
type 1. A clinical study showed the effect of IV vitamin 
C therapy on reduction of IgG and IgM antibody levels 
in EBV infection [12]. There is also a report of a case of 
enterovirus/rhinovirus-induced ARDS where the infu-
sion of HDIVC was associated with rapid resolution of 
lung injury [13].
Some studies showed that serum vitamin C levels may 
plummet in some patients especially in the critically ill 
during the course of infection [27, 28]; and vitamin C 
deficiency may contribute to organ injury and immune 
dysfunction which leads to the assumption that high 
doses of vitamin C might improve clinical outcomes of 
critically ill patients [27]. There is also some evidence 
that shows vitamin C may reduce patients’ susceptibility 
to lower respiratory tract infections such as pneumonia 
and it may have a protective role in lung infections, but 
further studies need to evaluate the efficacy of treatment 
with vitamin C in severe viral respiratory tract infections 
[27–31].
Meta-analyses demonstrated that the use of intrave-
nous vitamin C as a therapy for sepsis and ARDS has 
benefits such as a lower rate of vasopressor require-
ments, shorter duration of both mechanical ventilation 
and admission in the ICUs; along with a shorter hospital 
admission in critically ill patients [19, 32–34]. Lin et  al. 
found that administration of more than 50  mg/kg daily 
vitamin C had a significant effect in reduction of mor-
tality rate in patients with severe sepsis. They concluded 
that a better survival rate correlated with administration 
of high doses of vitamin C [35]. Fowler et  al. reported 
in their randomized, double-blind, placebo-controlled, 
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Table 1 Demographic characteristics, underlying diseases, clinical and laboratory findings, and outcomes
SD standard deviation, n count, IQR interquartile range (25–75%), COPD chronic obstructive pulmonary disease, WBC white blood cell, HB hemoglobin, PLT platelet, 
AST aspartate transaminase, ALT alanine transaminase, LDH lactate dehydrogenase, CRP C-reactive protein, ESR erythrocyte sedimentation rate, SPO2 oxygen 
saturation, ICU intensive care unit, PCR polymerase chain reaction
Group p
Case (n = 30) Control (n = 30)
Age (year), mean (SD) 57.53 (18.27) 61 (15.90) 0.436
Sex, n (%)
 Female 15 (50.00%) 15 (50.00%) > 0.9
 Male 15 (50.00%) 15 (50.00%)
Hypertension, n (%) 15 (50.00%) 10 (33.33%) 0.190
Diabetes mellitus, n (%) 12 (40.00%) 11 (36.67%) 0.791
Ischemic heart disease, n (%) 4 (13.33%) 7 (23.33%) 0.506
COPD, n (%) 3 (10.00%) 3 (10.00%) > 0.9
Thyroid disease, n (%) 2 (6.67%) 3 (10.00%) > 0.9
Fever, n (%) 7 (23.33%) 19 (63.33%) 0.002
Chill, n (%) 7 (23.33%) 9 (30.00%) 0.559
Dyspnea, n (%) 25 (83.33%) 21 (70.00%) 0.222
Myalgia, n (%) 4 (13.33%) 18 (60.00%) < 0.001
Weakness, n (%) 2 (6.67%) 4 (13.33%) 0.671
Cough, n (%) 26 (86.67%) 23 (76.67%) 0.506
Sputum, n (%) 1 (3.33%) 4 (13.33%) 0.353
Headache, n (%) 3 (10.00%) 8 (26.67%) 0.181
Vomit, n (%) 4 (13.33%) 2 (6.67%) 0.671
Chest pain, n (%) 2 (6.67%) 5 (16.67%) 0.424
Hemoptysis, n (%) 0 (0%) 3 (10.00%) 0.237
Positive PCR, n (%) 22 (73.33%) 30 (100.00%) > 0.9
Negative PCR, n (%) 8 (26.66%) 0 (00.00%)
WBC count (× 103/µl), mean (SD) 6.60 (3.65) 6.43 (3.69) 0.861
Lymphocyte (count/µl), mean (SD) 1082.68 (582.17) 1042.52 (590.81) 0.792
HB (g/dl), mean (SD) 13.35 (2.29) 12.65 (2.06) 0.218
PLT (× 103/µl), mean (SD) 194.20 (83.75) 203.30 (74.64) 0.658
AST (u/l), mean (SD) 35.93 (15.92) 33.93 (13.96) 0.607
ALT (u/l), mean (SD) 31.73 (8.57) 34.43 (9.69) 0.258
LDH (u/l), mean (SD) 619.20 (212.10) 599.67 (197.93) 0.714
CRP (mg/dl), mean (SD) 41.30 (28.86) 58.13 (52.80) 0.132
ESR (mm/hour), mean (SD) 60.00 (30.71) 66.03 (30.45) 0.448
Body temperature upon admission(°C), mean (SD) 37.03 (0.80) 37.93 (0.92) < 0.001
3rd day temperature (°C), mean (SD) 36.73 (0.36) 37.24 (0.69) 0.001
Body temperature at discharge (°C), mean (SD) 36.76 (0.47) 36.85 (0.46) 0.454
SPO2 upon admission (%), median (IQR) 86.0 (82.0–88.0) 87.5 (85.0–88.0) 0.148
3rd day  SPO2 (%), median (IQR) 90.5 (88.0–92.0) 88.0 (80.0–91.0) 0.014
SPO2 at discharge (%), median (IQR) 93.5 (91.0–95.0) 92.5 (92.0–94.0) 0.406
ICU length of stay (day), median (IQR) 5.50 (5.0–10.0) 5.0 (5.0–7.0) 0.381
Hospital length of stay (day), median (IQR) 8.50 (7.0–12.0) 6.50(4.0–12.0) 0.028
Expire, n (%) 3 (10.00%) 3 (10.00%) > 0.9
Intubation, n (%) 5 (16.67%) 4 (13.33%) > 0.9
Corticosteroid treatment, n (%) 8 (26.66%) 7 (23.33%) 0.77
Severity score, mean (/10) (SD) 3.57 (1.357) 3.40 (1.476) 0.651
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multicenter trial that high doses of vitamin C did not sig-
nificantly improve organ dysfunction scores in patients 
with severe sepsis or ARDS but in three secondary 
outcomes, use of vitamin C was associated with a sig-
nificantly lower risk of mortality on the 28th day after 
diagnosis of the infection (29.8% vs. 46.3%), a higher 
number of ventilator-free days (13.1 vs. 10.6 days) and a 
higher number of ICU-free days (10.7 vs. 7.7 days) [36].
All these findings emphasize possible beneficial effects 
of vitamin C as a treatment for COVID-19. Here, we 
conducted a randomized clinical trial with 60 patients in 
two groups. Thirty patients were treated with 1.5 g of IV 
vitamin C, every 6  h for 5  days in addition to the main 
treatment regimen (case group), whereas the other 30 
patients were treated only with the standard regimen. 
Demographic characteristics, underlying diseases, and 
clinical and laboratory findings were not significantly dif-
ferent between the two groups. Fever and myalgia were 
significantly more frequent in the control group but, 
other clinical findings were not notably different.  SpO2 
was improved in all patients. There is a similar report 
of  SpO2 improvement associated with treatment with 
HDIVC (doses range from 2 to 10 g per day in 8–10-h IV 
infusions) in 50 moderate-to-severe COVID-19 patients. 
They also reported that all patients were cured and dis-
charged [37]. However, the absence of a control group 
weakened the conclusions based on this report.
In the present study, there was no significant differ-
ence in oxygen  SpO2 levels between the two groups at 
discharge, but the median of  SpO2 levels were signifi-
cantly higher in the case group on the 3rd day of admis-
sion. The mean body temperature significantly decreased 
during the admission in both groups and there was no 
significant difference between two groups regarding the 
core body temperature at discharge but, on the 3rd day 
of treatment, the mean of patients’ body temperature was 
significantly lower in the case group. Length of stay in 
the hospital had a median of 8.5  days and it was unex-
pectedly higher in the case group (8.5 vs. 6.5, p = 0.028). 
Other outcomes including number of deaths, number 
of intubations and duration of ICU admission were not 
significantly different between two groups. We did not 
find any side effects in the patients. Other studies also 
reported good tolerance of HDIVC in their trials [38].
There are not enough data and clinical trials that have 
evaluated the correlation between HDIVC treatment 
in COVID-19 patients with ARDS and improvement 
of their status, but there are several ongoing studies 
that aim to investigate the impact of high-dose vitamin 
C on COVID-19 patients (details of ongoing studies 
are presented in Table  2). Investigators in these studies 
will assess primary outcomes such as 50% reduction in 
symptoms score in 28 days, incidence of adverse effects 
(including severe adverse reactions), time to clinical 
improvement (TTIC), TTIC of National Early Warning 
Score 2 (NEWS2), number of hospital admission days, 
the rate of decline in lung infection rate, in-hospital mor-
tality rates and number of ventilator-free days. The find-
ings of these studies will be valuable and we hope to see 
promising results in their studies.
It is worthy to note that some studies have used higher 
doses of vitamin C in their patients [39, 40]. The highest 
dose was used in the work of Zhang et al. who have used 
24 g daily in the form of 12 g of vitamin C/50 ml every 
12  h for 7  days at a rate of 12  ml/h. Although they did 
not find superior results in terms of improving invasive 
Fig. 2 Body temperature means through time in the case and 
control groups
Fig. 3 Distribution of severity scores of patients in each group
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mechanical ventilation-free days in 28 days (IMVFD28), 
but have found improving PaO2/FiO2 and hence benefit-
ing oxygenation for critically ill patients [39]. Marik et al. 
also suggested MATH + protocol for COVID-19 patients, 
including methylprednisolone, ascorbic acid, thiamine, 
heparin, and supplemental oxygen. They suggest using 
vitamin C 3  g IV q 6  hourly for at least 7  days or until 
transferred out of ICU [40]. There are also other large 
randomized controlled trials (RCTs) using different doses 
of vitamin C. The largest RCT is the Lessening Organ 
Table 2 Identifier and  details of  studies which investigated the  advantages of  high-dose vitamin C in  patients 
with COVID-19
CT clinical trial, O observational study, R randomized, N/A not available, N/R non-randomized, T triple blinded, Q quadruple blinded, D double blinded, O/L open label
*ClinicalTrials.gov
**irct.ir
Identifier Study type Estimated 
enrollment
Allocation Masking Arms Primary outcome measures
NCT04401150 CT 800 R Q Arm 1: Vitamin C: 50 mg/kg of 
weight administered intrave-
nously every 6 h for 96 h (16 
doses)
Arm 2: Normal saline (0.9% NaCl) 
or dextrose 5% in water (D5W) 
in a volume to match the 
vitamin C
Death or persistent organ dys-
function
NCT04342728* CT 520 R O/L Arm 1: 8000 mg of ascorbic acid 
(daily with food)
Arm 2: 50 mg of zinc gluconate 
(daily)
Arm 3: 8000 mg of ascorbic acid 
and 50 mg of Zinc gluconate
Symptom Reduction in 28 days
NCT04357782 CT 20 N/R O/L Arm 1: 50 mg/kg l-ascorbic acid 
(every 6 h for 4 days) in the 
group with mild deoxygena-
tion
Arm 2: 50 mg/kg l-ascorbic 
acid(every 6 h for 4 days) in the 
group with sever deoxygena-
tion
1. Incidence of adverse events
2. Incidence of serious adverse 
reactions
3. Incidence of adverse reactions
NCT04323514 O 500 N/A O/L 10 g of vitamin C intravenously 
in addition to conventional 
therapy
In-hospital mortality
NCT04344184* CT 200 R Q Arm 1: 100 mg/kg intravenous 
vitamin C infusion (every 8 h 
3 days)
Arm 2: Dextrose 5% Water
Ventilator-free days
NCT04264533* CT 140 R T Arm 1: 50 ml injection: 12 g 
vitamin C + Water
(every 12 h for 7 days)
Arm 2: 50 ml of sterile water 
(every 12 h for 7 days)
Ventilation-free days
IRCT20190917044805N2** CT 60 R D Arm 1: 200 ml volume including 
12,000 mg of vitamin C in 
dextrose 5% for 4 days
Arm 2: 200 ml of Distilled water 
in dextrose 5%
1. Time to clinical improvement 
(TTIC)
2. Time to clinical improvement 
(TTIC) of NEWS2 (National Early 
Warning Score 2)
IRCT20200324046850N5** CT 40 R D Arm 1: Main regime + 500 mg of 
vitamin C
Arm 2: Main regime + Placebo of 
vitamin C
Number of hospital admission 
days
IRCT20151228025732N52** CT 30 R O/L Arm 1: 2000 mg of vitamin C 
every 6 h for 7 days + main 
regime
Arm 2: Only the main regime
1. The rate of decline in lung 
infection rate
2. Number of breaths per minute
3. The course of the disease
4. Heart rate
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Dysfunction with Vitamin C-COVID (LOVIT-COVID) 
trial in Canada assessing efficacy of 50 mg/kg every 6 h 
vitamin C, i.e., equivalent to 15 g/day for a 75 kg person 
(NCT04401150). Another large study is underway in Italy 
recruiting 500 patients in whom use of 10  g vitamin C 
is being tested. [NCT04323514] Although the results of 
these trials will also help our understanding of the pre-
ferred dose of vitamin C in COVID-19 patients, the avail-
able results point to the fact that higher doses can also be 
safe and effective (compared to the six g daily dose used 
in this study).
Another important topic is the length of vitamin C 
administration. Some studies suggest better outcome 
by administering vitamin C for longer duration, i.e., for 
at least 7  days [40]. However, a recent meta-analysis 
and systematic review of 17 studies reporting the effect 
of vitamin C supplementation in COVID-19 concluded 
that the best duration for administering vitamin C is over 
3–4 days, with lower efficacy if used less than 3 days or 
more than 5 days [41].
Despite practicing proper randomization, certain fac-
tors were different between two groups (higher rate of 
myalgia and mean body temperature in control group), 
which can be overcome by having a larger patient pop-
ulation. Although by clinical judgment, one can assume 
that myalgia does not have much role in the prognosis of 
patients and given its subjectivity, it is of lower signifi-
cance compared to other important prognostic factors. 
Also for body temperature, in this study more empha-
sis was put on the progression of patient symptoms. By 
viewing the results at different days of hospitalization, 
one can see that at discharge, both groups had values 
below the threshold of considering as fever. Although 
there was a difference between groups (36.76 vs. 36.85), 
still this value is not considered in the threshold of fever.
Our study has its own limitations, which can be cov-
ered in the future studies. The open-label design of the 
study and relatively small patient population are the main 
limitations. Further randomized double-blind clinical tri-
als with more patient population can be beneficial.
Conclusion
In this study, we found that there were improvements in 
peripheral oxygen saturation and body temperature in 
both groups during the time of admission, but we did not 
find significantly better outcomes in the group who were 
treated with high-dose vitamin C in addition to the main 
treatment regimen at discharge.
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